RT Journal Article
SR Electronic
T1 Epidemics of chikungunya, Zika, and COVID-19 reveal bias in case-based mapping
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2021.07.23.21261038
DO 10.1101/2021.07.23.21261038
A1 Bustos Carrillo, Fausto Andres
A1 Mercado, Brenda Lopez
A1 Monterrey, Jairo Carey
A1 Collado, Damaris
A1 Saborio, Saira
A1 Miranda, Tatiana
A1 Barilla, Carlos
A1 Ojeda, Sergio
A1 Sanchez, Nery
A1 Plazaola, Miguel
A1 Laguna, Harold Suazo
A1 Elizondo, Douglas
A1 Arguello, Sonia
A1 Gajewski, Anna M.
A1 Maier, Hannah E.
A1 Latta, Krista
A1 Carlson, Bradley
A1 Coloma, Josefina
A1 Katzelnick, Leah
A1 Sturrock, Hugh
A1 Balmaseda, Angel
A1 Kuan, Guillermina
A1 Gordon, Aubree
A1 Harris, Eva
YR 2022
UL http://medrxiv.org/content/early/2022/03/11/2021.07.23.21261038.abstract
AB Accurate tracing of epidemic spread over space enables effective control measures. We examined three metrics of infection and disease in a pediatric cohort (N ≈ 3,000) over two chikungunya and one Zika epidemic, and in a household cohort (N=1,793) over one COVID-19 epidemic in Managua, Nicaragua. We compared spatial incidence rates (cases/total population), infection risks (infections/total population), and disease risks (cases/infected population). We used generalized additive and mixed-effects models, Kulldorf’s spatial scan statistic, and intracluster correlation coefficients. Across different analyses and all epidemics, incidence rates considerably underestimated infection and disease risks, producing large and spatially non-uniform biases distinct from biases due to incomplete case ascertainment. Infection and disease risks exhibited distinct spatial patterns, and incidence clusters inconsistently identified areas of either risk. While incidence rates are commonly used to infer infection and disease risk in a population, we find that this can induce substantial biases and adversely impact policies to control epidemics.Article summary line Inferring measures of spatial risk from case-only data can substantially bias estimates, thereby weakening and potentially misdirecting measures needed to control an epidemic.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThis study was supported by grants R01 AI099631 (AB), P01 AI106695 (EH), R01 AI120997 (AG), and U19 AI118610 (EH) from the National Institute of Allergy and Infectious Diseases of the National Institutes of Health; the National Institutes of Health Centers of Excellence for Influenza Research and Surveillance [contract: HHS 272201400006C (AG)]; and the Open Philanthropy Project Fund for the production of recombinant SARS-CoV-2 spike protein, its receptor binding domain, and antibodies at the University of Michigan Center for Structural Biology. FBC was partially supported by a supplement to grant P01 AI106695.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:The PDCS was approved by Institutional Review Boards of the University of California, Berkeley, the University of Michigan, Ann Arbor, and the Nicaraguan Ministry of Health. The HICS was approved by the University of Michigan, Ann Arbor and the Nicaraguan Ministry of Health. The parents or legal guardians of participants provided written informed consent. Subjects six years and older provided verbal assent.I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesIndividual-level data may be shared with outside investigators following UC Berkeley and UM Ann Arbor IRB approval. Data has been deposited in a HIPAA-compliant Dropbox account hosted by the University of Michigan and will be available by request, as is required by the IRB-approved protocols for the PDCS and the HICS. Please contact the UC Berkeley Center for the Protection of Human Subjects (ophs@berkeley.edu), Eva Harris (eharris@berkeley.edu), the University of Michigan Health Sciences and Behavioral Sciences IRB (irbhsbs@umich.edu), and Aubree Gordon (gordonal@umich.edu) to arrange for data access. Databases without names and other identifiable information were used for all analyses. Collaborating research groups and institutions will be sent coded data with all personal identifiers unlinked as well as data dictionaries and the accompanying R code.